ADVI Expert Discusses IRA Updates from Association for Value-Based Cancer Care (AVBCC) Summit

ADVI experts Alicia Silver, director of policy and reimbursement, Brenna Raines, director of policy and reimbursement, Josh Greenblatt, senior vice president of market access, Louis Jacques, MD, chief clinical officer, Marc Samuels, CEO and president, and senior advisor, Michael Kolodziej, MD attended the 2023 Association for Value-Based Cancer Care (AVBCC) Summit in New York, NY.

During the event, ADVI experts Brenna Raines and Michael Kolodziej, MD moderated a number of sessions including:

• IRA Impact: Pharma Translating Impact Over the Next 5 Years
• Value-Based Agreements in Oncology: What Cancer Care Practices are Doing in the Marketplace Today
• IRA Providers: Translating Impact Over the Next 5 Years
• Improving the Collaboration Between Oncology Practices and the PBM Industry
• Enhancing Oncology Model (EOM) Update

Hear Key Takeaways from the Event
If you couldn’t make it to the event to sit in on these conversations, listen in now as Brenna Raines discusses key takeaways from these sessions including key points on the Inflation Reduction Act (IRA), the government negotiation provision of drugs in Medicare, the small-molecule disadvantage or the “pill penalty”, narrow exclusion for orphan drugs, the impact of the IRA on innovation, the momentum of value-based arrangements, and whether CMS is able to do a true value assessment for drugs.

Learn More

Stay ahead of the curve. Get in touch today to gain expert insights on the Inflation Reduction Act, and the evolving healthcare landscape.

---

Brenna Raines, MHA
Vice President, Market Access and Policy Strategy